Comparing an ultrasound-based bone scan with standard DXA to diagnose osteoporosis
Compares REMS with DXA for diagnosing osteoporosis and predicting fractures in adults.
Plain-language title generated from the registry record
Registry title: REMS vs DXA for Osteoporosis Diagnosis and Fracture Risk Prediction
Key facts
- Where
- Easton and Salisbury, United StatesSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 90 years old?
Source: NCT07876882, who can take part
Where in United States
- Rheumatology Associates of DelmarvaEaston, United StatesTaking people
- Rheumatology Associates of DelmarvaSalisbury, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BoneVue Diagnostics
- Trial code
- NCT07876882
- Record updated
- 15 October 2026
- Original description
This prospective, observational, comparative diagnostic study will evaluate the performance of Radiofrequency Echographic Multi Spectrometry (REMS) for the diagnosis of osteoporosis and prediction of fragility fracture risk in a U.S. population, using dual-energy X-ray absorptiometry (DXA) as the reference standard. Approximately 250 male and female participants aged 30-90 years who are undergoing evaluation for bone health will be enrolled at Rheumatology Associates of Delmarva. Participants will have clinically obtained DXA results and undergo REMS assessment of the lumbar spine and proximal femur. Diagnostic performance, including sensitivity, specificity, predictive values, and concordance between REMS and DXA, will be evaluated. Participants will also be followed by telephone at 6 and 12 months to identify incident non-traumatic fragility fractures and assess the ability of REMS and DXA to predict fracture risk.Read full original descriptionShow less
Estimation of the Effectiveness of Radiofrequency Echographic Multi Spectrometry (REMS) for the Diagnosis of Osteoporosis and Fracture Risk Prediction in the United States in Comparison With Dual-Energy X-Ray Absorptiometry (DXA)
This prospective, observational, comparative diagnostic study will evaluate the performance of Radiofrequency Echographic Multi Spectrometry (REMS) for the diagnosis of osteoporosis and prediction of fragility fracture risk in a U.S. population, using dual-energy X-ray absorptiometry (DXA) as the reference standard. Approximately 250 male and female participants aged 30-90 years who are undergoing evaluation for bone health will be enrolled at Rheumatology Associates of Delmarva. Participants will have clinically obtained DXA results and undergo REMS assessment of the lumbar spine and proximal femur. Diagnostic performance, including sensitivity, specificity, predictive values, and concordance between REMS and DXA, will be evaluated. Participants will also be followed by telephone at 6 and 12 months to identify incident non-traumatic fragility fractures and assess the ability of REMS and DXA to predict fracture risk.
Inclusion: Age 30-90 years at time of enrollment; Presenting for evaluation of bone health or osteoporosis risk assessment; Has undergone a clinically ordered DXA scan (lumbar spine, proximal femur) as part of routine medical care through the subject's healthcare provider within the seven days immediately preceding the REMS examination; Willing and able to provide written informed consent; Able to comply with study procedures, including telephone follow-up interviews at 6- and 12-months post-enrollment.
Exclusion: Declared pregnancy as collected per standard of care prior to DXA; Inability to provide written informed consent; Inability to complete an adequate REMS examination.